Fireside Chat with Theranos Whistleblowers
|
By AACC Posted on 12 Jul 2022 |

Image: Fireside Chat with Theranos Whistleblowers Erika Cheung and Tyler Shultz (Photo courtesy of aacc.org)
Tuesday, July 26
1 p.m. U.S. Central Time
Room S100
McCormick Place Convention Center
Erika Cheung and Tyler Shultz—two of the key whistleblowers who helped bring down Theranos—will speak in a special fireside chat. In this session, Cheung and Shultz will discuss the ethical challenges they faced in their efforts to reveal Theranos’ fraud and protect patients from the company’s faulty tests.
After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the U.S. However, when laboratory experts were finally able to evaluate Theranos’ actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology’s capabilities.
Cheung and Shultz worked with fellow whistleblowers to reveal—both to federal regulators and the press—that the Theranos laboratory actively put patients at risk of misdiagnosis and harm by offering them unreliable tests. Cheung later testified at Holmes’ trial as well. It is in large part thanks to the courage of these whistleblowers that Theranos was shut down and Holmes convicted of fraud.
Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting. Specifically, they will focus on the ethics of the situation they found themselves in at Theranos, as well as the overall ethical obligations of clinical laboratories and the vital role laboratory medicine professionals play in keeping patients safe. The discussion will be moderated by AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes’ trial.
1 p.m. U.S. Central Time
Room S100
McCormick Place Convention Center
Erika Cheung and Tyler Shultz—two of the key whistleblowers who helped bring down Theranos—will speak in a special fireside chat. In this session, Cheung and Shultz will discuss the ethical challenges they faced in their efforts to reveal Theranos’ fraud and protect patients from the company’s faulty tests.
After Theranos launched its retail testing service in 2013, it quickly gained national prominence with its promise of revolutionizing the way lab testing works in the U.S. However, when laboratory experts were finally able to evaluate Theranos’ actual science at the 2016 AACC Annual Scientific Meeting, Theranos CEO Elizabeth Holmes was unable to dispel suspicions that she was lying about her technology’s capabilities.
Cheung and Shultz worked with fellow whistleblowers to reveal—both to federal regulators and the press—that the Theranos laboratory actively put patients at risk of misdiagnosis and harm by offering them unreliable tests. Cheung later testified at Holmes’ trial as well. It is in large part thanks to the courage of these whistleblowers that Theranos was shut down and Holmes convicted of fraud.
Cheung and Shultz will discuss their experience with getting the truth out about Theranos on July 26 at the 2022 AACC Annual Scientific Meeting. Specifically, they will focus on the ethics of the situation they found themselves in at Theranos, as well as the overall ethical obligations of clinical laboratories and the vital role laboratory medicine professionals play in keeping patients safe. The discussion will be moderated by AACC President Dr. Stephen R. Master, who himself served as an expert witness in Elizabeth Holmes’ trial.
Latest AACC 2022 News
- AACC 2022 Review: International Meetings Rebound After Suffering Long COVID Hiatus
- Faster Method Diagnoses Pediatric Urinary Tract Infections
- Tianlong Showcases Integrated PCR Lab Solutions at AACC 2022
- Cellavision Introduces New Workflow Solution for Low-Volume Hematology Labs at AACC 2022
- Advanced Instruments Introduces New Automated Osmometer at AACC 2022
- Innovative Smartphone and AI-Based Tests Featured at AACC 2022
- New Tests Presented at AACC 2022 to Solve Challenges in Children's Healthcare
- 10-Minute Sepsis Risk Stratification Test Introduced at AACC 2022
- New System Combining DNA/RNA Extraction and Smart PCR Setup Launched at AACC 2022
- Novel Small Volume Blood Collection Device Launched at AACC 2022
- AACC Disruptive Technology Award Finalists Tackle Cancer, Women's Health, and STDs
- Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022
- Nikon Instruments Displays Latest Clinical Pathology Products at AACC 2022
- Seegene Showcases Latest Molecular Testing Solutions at AACC 2022
- Werfen Introduces New Acute Care Diagnostic Products for CVOR at AACC 2022
- PerkinElmer Demonstrates Vanadis NIPT Screening Platform Featuring Groundbreaking cfDNA Technology
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more








